61
Views
6
CrossRef citations to date
0
Altmetric
Review

Novel treatment strategies for aggressive non-Hodgkin’s lymphoma

&
Pages 733-748 | Published online: 24 Mar 2006

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Matthew Ong Beng Seng, David Meyer, Stephen Gichuhi, Louis Tong, Sridharan Sudharshan, Jyotirmay Biswas, Ilaria Testi & Rupesh Agrawal. (2020) Ocular Surface Disorders in Patients with Human Immunodeficiency Virus (HIV) Infection. Ocular Immunology and Inflammation 28:7, pages 1015-1021.
Read now

Articles from other publishers (4)

Fritz OffnerOlga SamoilovaEvgenii OsmanovHyeon-Seok EomMax S. ToppJoão RaposoViacheslav PavlovDeborah RicciShalini ChaturvediEugene ZhuHelgi van de Velde, Christopher EnnyAleksandra RizoBurhan Ferhanoglu. (2015) Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood 126:16, pages 1893-1901.
Crossref
Anne-Sophie Michallet & Bertrand Coiffier. (2009) Recent developments in the treatment of aggressive non-Hodgkin lymphoma. Blood Reviews 23:1, pages 11-23.
Crossref
Catherine Thieblemont & Bertrand Coiffier. (2007) Lymphoma in Older Patients. Journal of Clinical Oncology 25:14, pages 1916-1923.
Crossref
. (2006) Current Awareness in Hematological Oncology. Hematological Oncology 24:4, pages 238-245.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.